Eric Leire (CEO) Genflow Biosciences PLC (LSE:GENF) Presenting at the proactive One2One Virtual Forum – 20th January 2022
Genflow Biosciences PLC, a UK-based biotechnology company is developing gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases.
This will be done through novel therapeutics targeting ageing in humans by using genetically modified adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant that is found in centenarians.
SIRT6 has already been shown to have improved capabilities to repair DNA damage. This will improve health spans (living healthier for longer) and potentially, life expectancy.
Genflow primarily seeks to develop its lead compound, GF-1002, a recombinant self-complementary AAV containing a transgene encoding the cDNA (coding DNA) portion of a variant of the human SIRT6 gene found in centenarians, that has already yielded promising pre-clinical results.
source